SCHEDULE 13G/A: Farallon Capital Affiliates Disclose Significant Passive Stake in Agios Pharmaceuticals

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing their collective beneficial ownership of up to 9.9% of Agios Pharmaceuticals, Inc.'s common stock as of December 31, 2024, affirming a passive investment strategy.

Summary

• Farallon Capital Partners, L.P. and various affiliated funds (collectively, 'Farallon Funds') reported beneficial ownership of common stock in Agios Pharmaceuticals, Inc.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a routine update to previously reported ownership.
• Farallon Healthcare Partners Master, L.P. holds 3,329,016 shares, representing 5.8% of the class.
• Farallon Partners, L.L.C., as the general partner for several Farallon Funds, is deemed to beneficially own 5,452,393 shares, or 9.6% of the class.
• Several individual managing members and senior managing members of Farallon's general partners, including Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, are each deemed to beneficially own 5,674,466 shares, representing 9.9% of the class.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Agios Pharmaceuticals, Inc., other than activities solely in connection with a nomination under Rule 14a-11.
• The address of Agios Pharmaceuticals, Inc. is 88 Sidney Street, Cambridge, Massachusetts, 02139.
• The principal business office for all Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership. It does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's performance or outlook. The stated intent is passive investment.

Future Outlook

NA

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11."
• "Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares."

Industry Context

This filing is a routine disclosure of a significant passive investment by a major investment firm in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Farallon Capital maintains a substantial stake in Agios Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive investment stance by Farallon Capital, which may offer some stability perception.

Key Dates

Keywords

Agios Pharmaceuticals, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment, Biotechnology, Pharmaceuticals